| Ticker | Status | Jurisdiction | Filing Date | CP Start | CP End | CP Loss | Deadline |
|---|
| Ticker | Case Name | Status | CP Start | CP End | Deadline | Settlement Amt |
|---|
| Ticker | Name | Date | Analyst Firm | Up/Down | Target ($) | Rating Change | Rating Current |
|---|
On Friday, Virpax Pharmaceuticals, Inc. (NASDAQ:VRPX) completed the full study following the initial Probudur pilot study performed by the U.S. Army Institute of Surgical Research (USAISR) under an existing Cooperative Research and Development Agreement (CRADA).
The USAISR is the U.S. Department of Defense’s premier research organization for developing solutions for trauma and critical care challenges in combat casualties.
The study was designed to determine if Probudur reduces pain behaviors in a rat model of incisional pain.
The surgical procedures and assessments were identical to those in the pilot study. The study compared Probudur with free bupivacaine and Pacira Pharmaceuticals Inc’s (NASDAQ:PCRX) non-opioid analgesic pain killer, Exparel.
Various concentrations of Probudur were injected into the tissue around the incision site, and a saline solution was used for the control group.
The doses of Probudur showed a reduction in incision-induced pain behaviors.
Probudur is being developed to achieve the overall goal of safe and effective pain control during the perioperative period and to significantly reduce or eliminate the need for opioids after surgery in approved indications.
Probudur is a local anesthetic that binds to the sodium channels, preventing pain signals from reaching the brain.
In preclinical studies, Probudur has shown long-duration pain control for at least 96 hours, with a rat incisional model demonstrating analgesia for up to five days and in vitro studies demonstrating a slow release of bupivacaine lasting up to six (6) days.
Price Action: VRPX stock is up 31.5% at $0.38 at last check Friday.
Read Next:
Photo by MargJohnsonVA via Shutterstock
